Did You Know...
...that Charles Goodyear performed some of his experiments on rubber while in debtor's prison? He was there so often he referred to it as his "hotel". Chronically in debt because of poor business sense and ill health, Goodyear depended on the generosity of friends and family. Even after he unlocked the secret to vulcanizing rubber, he was unable to improve his financial situation. When he died, his estate was $200,000 in debt.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173626 | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment t... | 05/08/2012 |
| 8158613 | Topical pharmaceutical formulations and methods of treatment In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium the... | 04/17/2012 |
| 8097606 | Antiglucocorticoids for the treatment of catatonia The invention provides a method of ameliorating the symptoms of catatonia in a patient who is in need of treatment for catatonia. The method comprises administration of a therapeutically effective amount of a glucocorticoid receptor antagonist to the patient. ... | 01/17/2012 |
| 8058266 | Methods and compositions for treatment of macular and retinal disease The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention inclu... | 11/15/2011 |
| 8053426 | Progesterone receptor antagonists The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group. ... | 11/08/2011 |
| 7951790 | Progesterone receptor antagonists The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group. ... | 05/31/2011 |
| 7902178 | Progesterone receptor antagonists The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group. ... | 03/08/2011 |
| 7829555 | Drug targeting The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel bioreductive conjugates compr... | 11/09/2010 |
| 7820642 | Nandrolone 17β-carbonates Disclosed are compounds of the formula (I) wherein R is C1-C30 alkyl, which may be optionally further substituted with one or more of C5-C8 cycloalkyl groups, or a C5-C... | 10/26/2010 |
| 7799770 | Solid body forms of mesoprogestin 11β-{4E-(hydroxyiminomethyl)-phenyl}-17α methoxymethyl-17β-methoxy-estra-4,9-dien-3-one The invention relates to novel solid body forms of mesoprogestin 11β-[4E-(hydroxyiminomethyl)-phenyl]-17α-methoxymethyl-17β-methoxy-estra-4,9-dien-3-one (oxime J 867), particularly a highly pure and stable amorphous or highly crystalline form (ansolvate/anhydrate... | 09/21/2010 |
| 7781421 | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the α-c... | 08/24/2010 |
| 7759330 | 21-substituted progesterone derivatives as new antiprogestational agents A compound having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH... | 07/20/2010 |
| 7704985 | Treatment of irritable bowel syndrome and related bowel diseases The present invention discloses a method of treating an individual having irritable bowel syndrome or a related disorder, comprising the step of administering to said individual a pharmacologically effective dose of a luminally active anti-inflammatory or immunosupp... | 04/27/2010 |
| 7638508 | Glucocorticosteroid compound having anti-inflammatory activity A compound of formula (I): wherein X represents O or S; R1 represents C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkylmethyl or C3-8 cycloalkenyl ... | 12/29/2009 |
| 7632826 | Use of agonists of the glucocorticosteroid and/or mineralo-corticosteroid receptors, in particular corticosteroids for the treatment of addiction Corticosteroid receptors and/or mineralo-corticoid receptors are administered in combination with an addictive drug or the pharmacodynamic equivalent thereof for the therapy of an addictive disease triggered by said addictive drug or connected thereto. ... | 12/15/2009 |
| 7579335 | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched alkyl group, a bicycloalkyl group, or a C5-C6 cycloalky... | 08/25/2009 |
| 7572781 | Prodrugs for use as ophthalmic agents The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring stero... | 08/11/2009 |
| 7550451 | Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy The invention relates to new compounds of general formula I, their production and pharmaceutical preparations that contain these compounds. The compounds according to the invention are preferably used for female bir... | 06/23/2009 |
| 7538100 | 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations The invention relates to 17α-alkyl-17β-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17β-hydroxy-estra-1,3,5(10)-trienes as intermediate ... | 05/26/2009 |
| 7538099 | Antiprogestin method and kit for reducing side effects associated with low dosage HRT, oral contraception and regulating menses Menses regulation and, when desired, contraception is achieved at low doses of estrogen and progestin, which otherwise would create episodes of breakthrough bleeding and/or withdrawal amenorrhea, by periodically inducing menses with an antiprogestin. ... | 05/26/2009 |
| 7521439 | Glucocorticoid receptor ligands for the treatment of metabolic disorders This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin... | 04/21/2009 |
| 7435757 | 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C | 10/14/2008 |
| 7419971 | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application Methods and compositions for enhancing the activity and/or duration of action of soft anti-inflammatory steroids of the haloalkyl 17α-alkoxy-11β-hydroxyandrost-4-en-3-one-17β-carboxylate type and the corresponding Δ1,4 compounds and of anti-inflammato... | 09/02/2008 |
| 7410959 | Therapeutic uses for aminosterol compounds A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may... | 08/12/2008 |
| 7402578 | Methods for inhibiting cognitive deterioration in adults with down's syndrome This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing or reversing cognitive deterioratio... | 07/22/2008 |
| 7390796 | Fatty acid modified forms of glucocorticoids Compounds are disclosed of the formula in which R3 is C8 to C24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly by inhalati... | 06/24/2008 |
| 7378404 | 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens This invention describes the new 8β-substituted estratrienes of general formula I in which R2, R3, R6, R6′, R7, R7′, R9, R11, R11′, R12, R14 | 05/27/2008 |
| 7374747 | Pharmaceutical foam The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized contained comprising a quick-breaking alcoholic foaming agent, such that when the composit... | 05/20/2008 |
| 7368426 | Methods for the therapeutic use of cyclosporine components Methods of treating humans or animals having rheumatoid arthritis are disclosed which include topically administering a therapeutically effective amount of a cyclosporine component to the human or animal, thereby treating the rheumatoid arthritis. ... | 05/06/2008 |
| 7368442 | Nitrate esters of corticoid compounds and pharmaceutical applications thereof Compounds of the formula and use of the compounds as medicaments. ... | 05/06/2008 |
| 7361646 | Methods for treating gastroesophageal reflux disease This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating gastroesophageal reflux disease in a subject. ... | 04/22/2008 |
| 7361645 | Androgenic 7-substituted 11-halogen steroids The invention relates to 11β-halogen steroids with general formula (I), whereby R11 is halogen, X—Y-Z represents a group with one of the two structures CH═C—C or CH2—C═C and the other radicals have the meaning that is indicated in th... | 04/22/2008 |
| 7329402 | Methods of imaging and treatment Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The... | 02/12/2008 |
| 7326697 | Methods for increasing the therapeutic response to electroconvulsive therapy This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to the glucocorticoid receptor can be used in methods of increasing the therapeutic response to el... | 02/05/2008 |
| 7323454 | Etonogestrel esters The subject invention provides new progestogen esters and uses thereof. ... | 01/29/2008 |
| 7320968 | Pharmaceutical composition A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhanc... | 01/22/2008 |
| 7304073 | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors The present invention concerns a method of treatment or prevention of myocardial ischemia-reperfusion injury by diagnosing that a person is in need of treatment or prevention of myocardial ischemia-reperfusion injury and administering a therapeutically effective amo... | 12/04/2007 |
| 7304171 | Compounds and methods for cytoprotection Compounds, compositions and methods for treating degenerative diseases and disorders are disclosed, the compounds having the following structure (I): including stereoisomers, prodrugs and pharmaceutically accepta... | 12/04/2007 |
| 7291608 | Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α There are provided compounds of formula (I) wherein the variables are as defined by the present specification; and solvates thereof, processes for preparing them and their use in therapy. ... | 11/06/2007 |
| 7291609 | Specific glucocorticosteroid compound having anti-inflammatory activity A compound of formula (I): or a physiologically acceptable solvate thereof. ... | 11/06/2007 |
